@article{JTD33225,
author = {Xiao-Dong Jiao and Xi He and Bao-Dong Qin and Ke Liu and Ying Wu and Jun Liu and Ting Hou and Yuan-Sheng Zang},
title = {The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {11},
year = {2019},
keywords = {},
abstract = {Background: Tumor mutation burden (TMB) is novel biomarker of promising predict value in prediction of immune checkpoint inhibitors (ICPis) in non-small cell lung cancer (NSCLC). However, the distribution of TMB in epidermal growth factor receptor (EGFR)-mutant advanced lung adenocarcinoma (LUAD) patients and the impact on overall survival (OS) time are not well demonstrated.
Methods: Information regarding gene mutations and patients’ survival time in advanced LUAD was downloaded from The Cancer Genome Atlas (TCGA) database. The diversity of TMB in different EGFR- mutant types was observed and the predicted value of TMB for OS as well as other co-mutations were analyzed. The diversity of TMB was also observed in another Chinese cohort of advanced LUAD patients.
Results: The median TMB values of EGFR wild-type, other types of EGFR mutations, exon 19 deletions and L858R were 6.12, 5.66, 3.77 and 4.72, differences between wild-type and EGFR sensitive mutations (exon 19 deletion or L858R) were significant (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/33225}
}